tretinoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
retinol derivatives	2722	302-79-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tretinoin potassium trans-Retinoic acid tretinoin sodium retinoic acid tretinoin	An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). Molecular weight: 300.44 Formula: C20H28O2 CLOGP: 6.74 LIPINSKI: 1 HAC: 2 HDO: 1 TPSA: 37.30 ALOGS: -4.80 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tretinoin potassium
trans-Retinoic acid
tretinoin sodium
retinoic acid
tretinoin

An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).

Molecular weight: 300.44
Formula: C20H28O2
CLOGP: 6.74
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 37.30
ALOGS: -4.80
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.70 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Oct. 20, 1971	FDA	VALEANT INTL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	792.01	16.14	135	8037	968	63479882
Blepharospasm	260.21	16.14	73	8099	5923	63474927
Taste disorder	197.34	16.14	72	8100	13590	63467260
Epilepsy	152.87	16.14	73	8099	26992	63453858
Idiopathic intracranial hypertension	137.74	16.14	38	8134	2893	63477957
Product use in unapproved indication	131.03	16.14	137	8035	178943	63301907
Intracranial pressure increased	96.20	16.14	33	8139	5194	63475656
Migraine	86.27	16.14	85	8087	103261	63377589
Gastrooesophageal reflux disease	86.11	16.14	82	8090	95557	63385293
Memory impairment	78.32	16.14	81	8091	104177	63376673
Hypoaesthesia	78.05	16.14	102	8070	168291	63312559
Leukaemia recurrent	75.29	16.14	20	8152	1318	63479532
Paraesthesia	61.98	16.14	88	8084	156878	63323972
Abdominal pain upper	46.61	16.14	90	8082	206354	63274496
Dry skin	45.95	16.14	46	8126	56841	63424009
Haematopoietic neoplasm	43.01	16.14	7	8165	36	63480814
Abortion spontaneous	41.54	16.14	40	8132	47155	63433695
Polyarteritis nodosa	34.95	16.14	8	8164	283	63480567
Lower respiratory tract infection fungal	33.74	16.14	8	8164	331	63480519
Dysphoria	32.99	16.14	15	8157	4951	63475899
Skin warm	31.59	16.14	15	8157	5461	63475389
Haemorrhagic diathesis	31.44	16.14	14	8158	4401	63476449
Off label use	30.81	16.14	169	8003	674293	62806557
Papilloedema	29.62	16.14	13	8159	3947	63476903
Xerosis	29.52	16.14	9	8163	973	63479877
Myelodysplastic syndrome	26.72	16.14	20	8152	16734	63464116
Disseminated intravascular coagulation	26.57	16.14	21	8151	19030	63461820
VIth nerve paralysis	26.27	16.14	8	8164	862	63479988
Chloroma	25.57	16.14	6	8166	237	63480613
Appetite disorder	24.73	16.14	14	8158	7307	63473543
Chromosomal deletion	24.40	16.14	5	8167	104	63480746
Arthritis infective	23.55	16.14	13	8159	6465	63474385
Dermatitis atopic	23.52	16.14	15	8157	9709	63471141
Skin exfoliation	22.91	16.14	28	8144	43074	63437776
Acne	22.90	16.14	21	8151	23272	63457578
Neutropenic sepsis	22.67	16.14	18	8154	16420	63464430
Drug intolerance	22.66	16.14	89	8083	308572	63172278
Vomiting	22.08	16.14	135	8037	559482	62921368
Acute myeloid leukaemia	22.00	16.14	18	8154	17129	63463721
Pain	21.71	16.14	166	8006	740462	62740388
Oesophageal mass	21.08	16.14	4	8168	55	63480795
Gambling	20.34	16.14	5	8167	241	63480609
Myocarditis	20.30	16.14	14	8158	10311	63470539
Thinking abnormal	19.92	16.14	14	8158	10629	63470221
Sweat gland tumour	18.48	16.14	4	8168	109	63480741
Contraindicated product administered	18.35	16.14	3	8169	217645	63263205
Arthropathy	18.17	16.14	4	8168	234788	63246062
Tenderness	17.74	16.14	18	8154	22560	63458290
Febrile neutropenia	16.88	16.14	43	8129	118406	63362444
Application site dryness	16.79	16.14	4	8168	169	63480681
Erythema	16.55	16.14	55	8117	175696	63305154

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	979.14	26.54	157	2671	1281	34952822
Idiopathic intracranial hypertension	203.09	26.54	37	2791	664	34953439
Hyperleukocytosis	121.75	26.54	29	2799	1973	34952130
Electrocardiogram QT prolonged	109.00	26.54	57	2771	40895	34913208
Haematopoietic neoplasm	82.61	26.54	12	2816	44	34954059
Acute myeloid leukaemia	77.44	26.54	35	2793	18235	34935868
Product use in unapproved indication	75.92	26.54	68	2760	117431	34836672
Leukaemia recurrent	70.85	26.54	18	2810	1597	34952506
Cytogenetic abnormality	54.58	26.54	13	2815	882	34953221
Hypokalaemia	46.25	26.54	38	2790	58176	34895927
Scrotal ulcer	45.51	26.54	10	2818	473	34953630
Hypomagnesaemia	40.46	26.54	24	2804	21827	34932276
Myelodysplastic syndrome	35.30	26.54	21	2807	19187	34934916
Febrile neutropenia	35.21	26.54	49	2779	136800	34817303
Neutropenia	34.33	26.54	52	2776	156726	34797377
IIIrd nerve paralysis	34.01	26.54	8	2820	514	34953589
Lymphopenia	30.38	26.54	18	2810	16317	34937786
Large granular lymphocytosis	28.84	26.54	6	2822	218	34953885
Jugular vein thrombosis	28.70	26.54	9	2819	1706	34952397
Extremity necrosis	27.47	26.54	9	2819	1963	34952140
Acute febrile neutrophilic dermatosis	26.75	26.54	8	2820	1295	34952808

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	1705.40	16.46	288	8840	2236	79733024
Idiopathic intracranial hypertension	261.44	16.46	63	9065	3159	79732101
Blepharospasm	179.49	16.46	53	9075	5798	79729462
Myelodysplastic syndrome transformation	160.32	16.46	32	9096	657	79734603
Product use in unapproved indication	139.60	16.46	157	8971	250202	79485058
Taste disorder	127.90	16.46	53	9075	15770	79719490
Hyperleukocytosis	127.33	16.46	34	9094	2576	79732684
Leukaemia recurrent	106.82	16.46	30	9098	2744	79732516
Intracranial pressure increased	85.00	16.46	33	9095	8289	79726971
Acute myeloid leukaemia	78.25	16.46	47	9081	30838	79704422
Epilepsy	78.05	16.46	52	9076	40808	79694452
Electrocardiogram QT prolonged	76.30	16.46	71	9057	90315	79644945
Haematopoietic neoplasm	72.22	16.46	12	9116	82	79735178
Cytogenetic abnormality	66.15	16.46	17	9111	1108	79734152
Migraine	61.19	16.46	62	9066	87431	79647829
Myelodysplastic syndrome	56.50	16.46	38	9090	30263	79704997
Abortion spontaneous	55.01	16.46	37	9091	29470	79705790
Hypoaesthesia	50.91	16.46	81	9047	179271	79555989
Gastrooesophageal reflux disease	48.96	16.46	60	9068	104186	79631074
Second primary malignancy	44.74	16.46	25	9103	14325	79720935
Hypercalcaemia	44.13	16.46	36	9092	38394	79696866
Memory impairment	44.11	16.46	59	9069	111675	79623585
Off label use	40.93	16.46	208	8920	907007	78828253
Febrile neutropenia	39.72	16.46	84	9044	230915	79504345
Papilloedema	37.63	16.46	17	9111	6216	79729044
Paraesthesia	37.38	16.46	70	9058	176253	79559007
Disseminated intravascular coagulation	35.84	16.46	31	9097	35811	79699449
Myocarditis	35.20	16.46	25	9103	21708	79713552
Neutropenia	34.61	16.46	91	9037	287619	79447641
Dysphoria	32.08	16.46	14	9114	4720	79730540
Polyarteritis nodosa	30.90	16.46	8	9120	537	79734723
Chloroma	28.16	16.46	8	9120	762	79734498
Lower respiratory tract infection fungal	27.03	16.46	8	9120	880	79734380
Acute promyelocytic leukaemia	26.86	16.46	9	9119	1482	79733778
Abdominal pain upper	26.09	16.46	70	9058	223749	79511511
Haemorrhagic diathesis	25.75	16.46	13	9115	6071	79729189
Dry skin	25.44	16.46	35	9093	67960	79667300
Gastrointestinal toxicity	24.93	16.46	14	9114	8095	79727165
Acute febrile neutrophilic dermatosis	24.78	16.46	11	9117	3861	79731399
IIIrd nerve paralysis	24.70	16.46	8	9120	1185	79734075
Hypomagnesaemia	23.64	16.46	28	9100	46883	79688377
Large granular lymphocytosis	23.56	16.46	6	9122	377	79734883
White blood cell count increased	22.94	16.46	35	9093	74598	79660662
Scrotal ulcer	22.87	16.46	6	9122	424	79734836
Chromosomal deletion	22.82	16.46	5	9123	163	79735097
Appetite disorder	22.81	16.46	13	9115	7726	79727534
VIth nerve paralysis	22.29	16.46	8	9120	1616	79733644
Ciliary body melanoma	22.15	16.46	3	9125	3	79735257
Dermatitis atopic	22.14	16.46	14	9114	10042	79725218
Skin warm	21.89	16.46	12	9116	6620	79728640
Photophobia	21.01	16.46	18	9110	20510	79714750
Oesophageal mass	20.69	16.46	4	9124	69	79735191
Extremity necrosis	20.29	16.46	9	9119	3152	79732108
Bone marrow necrosis	20.14	16.46	5	9123	283	79734977
Jugular vein thrombosis	20.10	16.46	10	9118	4528	79730732
Drug intolerance	19.94	16.46	71	9057	264048	79471212
Acute myeloid leukaemia recurrent	19.71	16.46	9	9119	3374	79731886
Arthritis infective	19.43	16.46	12	9116	8259	79727001
Endocarditis	19.06	16.46	13	9115	10584	79724676
Tenderness	18.83	16.46	18	9110	23624	79711636
Thinking abnormal	18.73	16.46	14	9114	13147	79722113
Completed suicide	18.45	16.46	3	9125	245764	79489496
Haemorrhage	17.84	16.46	35	9093	91083	79644177
Pericardial effusion	17.59	16.46	24	9104	46213	79689047
Pulmonary tuberculosis	17.44	16.46	11	9117	7854	79727406
Gelatinous transformation of the bone marrow	17.42	16.46	3	9125	26	79735234
Septic embolus	17.00	16.46	7	9121	2044	79733216

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D10AD01	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne
ATC	D10AD51	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne
ATC	L01XF01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Retinoids for cancer treatment
FDA CS	M0018962	Retinoids
CHEBI has role	CHEBI:22586	antioxidants
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:50176	keratolytic drugs
CHEBI has role	CHEBI:62488	signal molecules
CHEBI has role	CHEBI:63794	retinoid X receptor agonists
CHEBI has role	CHEBI:67079	anti-inflammatory agents
CHEBI has role	CHEBI:67198	retinoic acid receptor agonists
CHEBI has role	CHEBI:67199	activator protein-1 antagonists
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
FDA EPC	N0000175607	Retinoid
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D007641	Keratolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chloasma	indication	36209000
Acne vulgaris	indication	88616000
Acute promyelocytic leukemia, FAB M3	indication	110004001
Hyperkeratosis	indication	396228006
Facial Fine Wrinkling	indication
Solar Lentigines	indication
Fine Wrinkling	indication
Severe Recalcitrant Nodular Acne	indication
Kaposi's Sarcoma Skin Lesions	indication
Mottle Hyperpigmentation	indication
Keratosis follicularis	off-label use	48611009	DOID:2734
Lamellar ichthyosis	off-label use	205550003
Plane wart	off-label use	240539000
Primary cutaneous T-cell lymphoma	off-label use	400122007
Severe Recalcitrant Nodular Rosacea	off-label use
Osteomalacia	contraindication	4598005	DOID:10573
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Rectal hemorrhage	contraindication	12063002
Hypercholesterolemia	contraindication	13644009
Hearing loss	contraindication	15188001
Agranulocytosis	contraindication	17182001	DOID:12987
Myocardial infarction	contraindication	22298006	DOID:5844
Sunburn	contraindication	23346002
Atopic dermatitis	contraindication	24079001	DOID:3310
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Crohn's disease	contraindication	34000006
Depressive disorder	contraindication	35489007
Eczema	contraindication	43116000
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Vitiligo	contraindication	56727007	DOID:12306
Anorexia nervosa	contraindication	56882008	DOID:8689
Tinnitus	contraindication	60862001
Corneal opacity	contraindication	64634000
Ulcerative colitis	contraindication	64766004	DOID:8577
Osteoporosis	contraindication	64859006	DOID:11476
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Psychotic disorder	contraindication	69322001
Diabetes mellitus	contraindication	73211009	DOID:9351
Disorder of bone	contraindication	76069003	DOID:0080001
Congenital neutropenia	contraindication	89655007
Kidney disease	contraindication	90708001	DOID:557
Venous thrombosis	contraindication	111293003
Leukocytosis	contraindication	111583006
Mycosis fungoides	contraindication	118618005
Inflammatory disease of liver	contraindication	128241005
Bleeding	contraindication	131148009
Liver function tests abnormal	contraindication	166603001
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Telangiectasia disorder	contraindication	247479008
Dyspnea	contraindication	267036007
Edema	contraindication	267038008
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Keratoconjunctivitis sicca	contraindication	302896008	DOID:12895
Neutropenic disorder	contraindication	303011007	DOID:1227
Pericardial effusion	contraindication	373945007	DOID:118
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Fever	contraindication	386661006
Pseudomembranous enterocolitis	contraindication	397683000
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006
Severe diarrhea	contraindication	409587002
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Denuded skin	contraindication	418242004
Retinoic acid syndrome	contraindication	450887006
Pulmonary Infiltrates	contraindication
Pleural Effusions	contraindication
Predisposition To Hypertriglyceridemia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.17	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
3%;0.1%	TWYNEO	GALDERMA LABS LP	N214902	July 26, 2021	RX	CREAM	TOPICAL	9868103	Aug. 8, 2028	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
3%;0.1%	TWYNEO	GALDERMA LABS LP	N214902	July 26, 2021	RX	CREAM	TOPICAL	10653899	Dec. 30, 2030	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
3%;0.1%	TWYNEO	GALDERMA LABS LP	N214902	July 26, 2021	RX	CREAM	TOPICAL	10420743	July 12, 2038	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
0.05%	ALTRENO	DOW PHARM	N209353	Aug. 23, 2018	RX	LOTION	TOPICAL	10653656	Aug. 22, 2038	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
0.05%	ALTRENO	DOW PHARM	N209353	Aug. 23, 2018	RX	LOTION	TOPICAL	11324710	Aug. 22, 2038	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
3%;0.1%	TWYNEO	GALDERMA LABS LP	N214902	July 26, 2021	RX	CREAM	TOPICAL	July 26, 2024	NEW COMBINATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Retinoic acid receptor beta	Nuclear hormone receptor	P10826	RARB_HUMAN	AGONIST	EC50	6.70	WOMBAT-PK	CHEMBL
Retinoic acid receptor gamma	Nuclear hormone receptor	P13631	RARG_HUMAN	AGONIST	EC50	6.70	WOMBAT-PK	CHEMBL
Retinoic acid receptor alpha	Nuclear hormone receptor	P10276	RARA_HUMAN	AGONIST	EC50	6.70	WOMBAT-PK	CHEMBL
Nuclear receptor ROR-alpha	Nuclear hormone receptor	P35398	RORA_HUMAN		IC50	6.70	CHEMBL
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN		Ki	9.40	CHEMBL
Retinoic acid receptor RXR-beta	Nuclear hormone receptor	P28702	RXRB_HUMAN		Ki	9.30	CHEMBL
Retinoic acid receptor RXR-gamma	Nuclear hormone receptor	P48443	RXRG_HUMAN		Ki	8.85	CHEMBL
Peroxisome proliferator-activated receptor delta	Nuclear hormone receptor	Q03181	PPARD_HUMAN	AGONIST	Kd	7.80	IUPHAR
Nuclear receptor ROR-beta	Nuclear hormone receptor	Q92753	RORB_HUMAN	ANTAGONIST	IC50	9.82	IUPHAR
Nuclear receptor ROR-gamma	Nuclear hormone receptor	P51449	RORG_HUMAN		IC50	6.70	CHEMBL
Mitogen-activated protein kinase 1	Kinase	P28482	MK01_HUMAN		IC50	6.24	DRUG MATRIX
Nuclear receptor subfamily 2 group E member 1	Nuclear hormone receptor	Q9Y466	NR2E1_HUMAN	AGONIST	EC50	5.74	IUPHAR
Amyloid beta A4 protein	Unclassified	P05067	A4_HUMAN		IC50	6.75	CHEMBL
Nuclear receptor subfamily 2 group C member 2	Nuclear other	P49116	NR2C2_HUMAN	AGONIST	EC50	4.62	IUPHAR
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Unclassified	Q13526	PIN1_HUMAN		IC50	6.09	CHEMBL
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.64	DRUG MATRIX
Alpha-synuclein	Transporter	P37840	SYUA_HUMAN		IC50	5.52	CHEMBL
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.53	DRUG MATRIX
11-cis retinol dehydrogenase	Enzyme	Q92781	RDH1_HUMAN		Ki	7	WOMBAT-PK
Cellular retinoic acid-binding protein 1	Cytosolic other		RABP1_CHICK		IC50	6.43	CHEMBL
Retinoic acid receptor RXR-beta	Transcription factor		RXRB_MOUSE		Kd	6.51	CHEMBL
Retinoic acid receptor RXR-gamma	Transcription factor		RXRG_MOUSE		Kd	6.46	CHEMBL
Cellular retinoic acid-binding protein 1	Cytosolic other		RABP1_MOUSE		Kd	9.40	CHEMBL
Cellular retinoic acid-binding protein 2	Cytosolic other		RABP2_MOUSE		Kd	8.70	CHEMBL
Retinoic acid receptor alpha	Transcription factor		RARA_MOUSE		Kd	7.82	CHEMBL
Retinoic acid receptor RXR-alpha	Transcription factor		RXRA_MOUSE		Kd	6	CHEMBL
Retinoic acid receptor beta	Transcription factor		RARB_MOUSE		Kd	7.89	CHEMBL
Retinoic acid receptor gamma	Transcription factor		RARG_MOUSE		Kd	7.74	CHEMBL
Indoleamine 2,3-dioxygenase 2	Enzyme		I23O2_MOUSE		IC50	4.54	CHEMBL

External reference:

ID	Source
4018550	VUID
N0000146871	NUI
D00094	KEGG_DRUG
4018550	VANDF
C0040845	UMLSCUI
CHEBI:15367	CHEBI
3KV	PDB_CHEM_ID
CHEMBL38	ChEMBL_ID
DB00755	DRUGBANK_ID
D014212	MESH_DESCRIPTOR_UI
444795	PUBCHEM_CID
2644	IUPHAR_LIGAND_ID
2875	INN_ID
5688UTC01R	UNII
10753	RXNORM
46802	MMSL
5610	MMSL
d03863	MMSL
001954	NDDF
387305002	SNOMEDCT_US
54972005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Altreno	HUMAN PRESCRIPTION DRUG LABEL	1	0187-0005	LOTION	0.50 mg	TOPICAL	NDA	24 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5140	GEL	1 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5140	GEL	1 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5140	GEL	1 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5144	GEL	0.40 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5144	GEL	0.40 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5144	GEL	0.40 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5146	GEL	0.60 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5146	GEL	0.60 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5146	GEL	0.60 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5148	GEL	0.80 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5148	GEL	0.80 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5148	GEL	0.80 mg	TOPICAL	NDA	26 sections
Renova	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5150	CREAM	0.20 mg	TOPICAL	NDA	25 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5160	CREAM	0.25 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5160	CREAM	0.25 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5162	CREAM	0.50 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5162	CREAM	0.50 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5164	CREAM	1 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5164	CREAM	1 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5170	GEL	0.25 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5170	GEL	0.25 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5172	GEL	0.10 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5172	GEL	0.10 mg	TOPICAL	NDA	21 sections
TWYNEO	HUMAN PRESCRIPTION DRUG LABEL	2	0299-5945	CREAM	1 mg	TOPICAL	NDA	26 sections
TWYNEO	HUMAN PRESCRIPTION DRUG LABEL	2	0299-5945	CREAM	1 mg	TOPICAL	NDA	26 sections
TRI-LUMA	HUMAN PRESCRIPTION DRUG LABEL	3	0299-5950	CREAM	0.50 mg	TOPICAL	NDA	24 sections
TRI-LUMA	HUMAN PRESCRIPTION DRUG LABEL	3	0299-5950	CREAM	0.50 mg	TOPICAL	NDA	24 sections
TRI-LUMA	HUMAN PRESCRIPTION DRUG LABEL	3	0299-5950	CREAM	0.50 mg	TOPICAL	NDA	24 sections
Avita	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6140	GEL	0.25 mg	TOPICAL	NDA	22 sections